Literature DB >> 29201876

EGFR mutation positive non-small cell lung cancer: can we identify predictors of benefit from immune checkpoint inhibitors.

Ying Wang1, Peter Ellis1.   

Abstract

Entities:  

Year:  2017        PMID： 29201876      PMCID： PMC5690962          DOI： 10.21037/atm.2017.08.14

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  14 in total

Review 1.  Predictive biomarkers for checkpoint inhibitor-based immunotherapy.

Authors:  Geoffrey T Gibney; Louis M Weiner; Michael B Atkins
Journal:  Lancet Oncol       Date:  2016-12       Impact factor: 41.316

2.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Authors:  Susumu Kobayashi; Titus J Boggon; Tajhal Dayaram; Pasi A Jänne; Olivier Kocher; Matthew Meyerson; Bruce E Johnson; Michael J Eck; Daniel G Tenen; Balázs Halmos
Journal:  N Engl J Med       Date:  2005-02-24       Impact factor: 91.245

3.  Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Authors:  Esra A Akbay; Shohei Koyama; Julian Carretero; Abigail Altabef; Jeremy H Tchaicha; Camilla L Christensen; Oliver R Mikse; Andrew D Cherniack; Ellen M Beauchamp; Trevor J Pugh; Matthew D Wilkerson; Peter E Fecci; Mohit Butaney; Jacob B Reibel; Margaret Soucheray; Travis J Cohoon; Pasi A Janne; Matthew Meyerson; D Neil Hayes; Geoffrey I Shapiro; Takeshi Shimamura; Lynette M Sholl; Scott J Rodig; Gordon J Freeman; Peter S Hammerman; Glenn Dranoff; Kwok-Kin Wong
Journal:  Cancer Discov       Date:  2013-09-27       Impact factor: 39.397

4.  Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.

Authors:  Geoffrey R Oxnard; Maria E Arcila; Camelia S Sima; Gregory J Riely; Juliann Chmielecki; Mark G Kris; William Pao; Marc Ladanyi; Vincent A Miller
Journal:  Clin Cancer Res       Date:  2010-12-06       Impact factor: 12.531

5.  Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.

Authors:  Chee Khoon Lee; Johnathan Man; Sally Lord; Matthew Links; Val Gebski; Tony Mok; James Chih-Hsin Yang
Journal:  J Thorac Oncol       Date:  2016-10-17       Impact factor: 15.609

Review 6.  Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.

Authors:  Peter M Ellis; Emily T Vella; Yee C Ung
Journal:  Clin Lung Cancer       Date:  2017-02-16       Impact factor: 4.785

7.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

8.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

9.  Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.

Authors:  K Azuma; K Ota; A Kawahara; S Hattori; E Iwama; T Harada; K Matsumoto; K Takayama; S Takamori; M Kage; T Hoshino; Y Nakanishi; I Okamoto
Journal:  Ann Oncol       Date:  2014-07-09       Impact factor: 32.976

10.  Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.

Authors:  K Haratani; H Hayashi; T Tanaka; H Kaneda; Y Togashi; K Sakai; K Hayashi; S Tomida; Y Chiba; K Yonesaka; Y Nonagase; T Takahama; J Tanizaki; K Tanaka; T Yoshida; K Tanimura; M Takeda; H Yoshioka; T Ishida; T Mitsudomi; K Nishio; K Nakagawa
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976
View more
  4 in total

Review 1.  Personalized therapy for lung cancer: striking a moving target.

Authors:  Suchita Pakkala; Suresh S Ramalingam
Journal:  JCI Insight       Date:  2018-08-09

2.  Simultaneous Single Cell Gene Expression and EGFR Mutation Analysis of Circulating Tumor Cells Reveals Distinct Phenotypes in NSCLC.

Authors:  Sarah Owen; Ting-Wen Lo; Shamileh Fouladdel; Mina Zeinali; Evan Keller; Ebrahim Azizi; Nithya Ramnath; Sunitha Nagrath
Journal:  Adv Biosyst       Date:  2020-07-23

Review 3.  Rationale for Lung Adenocarcinoma Prevention and Drug Development Based on Molecular Biology During Carcinogenesis.

Authors:  Hongming Zhang; Liting Guo; Jibei Chen
Journal:  Onco Targets Ther       Date:  2020-04-14       Impact factor: 4.147

4.  Musashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC).

Authors:  Petr Makhov; Igor Bychkov; Bulat Faezov; Alexander Deneka; Alexander Kudinov; Emmanuelle Nicolas; Rohan Brebion; Eleanor Avril; Kathy Q Cai; Leonid V Kharin; Mark Voloshin; Elena Frantsiyants; Nikolay Karnaukhov; Oleg I Kit; Iuliia Topchu; Rushaniya Fazliyeva; Anna S Nikonova; Ilya G Serebriiskii; Hossein Borghaei; Martin Edelman; Essel Dulaimi; Erica A Golemis; Yanis Boumber
Journal:  Oncogenesis       Date:  2021-03-15       Impact factor: 7.485
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.